deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03265613

Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis (ADMSP)

Safety and Efficacy of Expanded Allogeneic Adipose-derived Mesenchymal Stem Cells in Patients With Moderate to Severe Psoriasis

Sponsor: Guangdong Provincial Hospital of Traditional Chinese Medicine

Conditions Drug Effect Drug Toxicity Mesenchymal Stromal Cells Psoriasis
Interventions adipose-derived multipotent mesenchymal stem cells
Updated 16 times since 2017 Last updated: Aug 23, 2023 Started: Sep 24, 2017 Primary completion: Aug 20, 2019 Completion: Nov 28, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03265613, this PHASE1/PHASE2 trial focuses on Drug Effect and Drug Toxicity and remains completed. Sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine, it has been updated 16 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Mar 2020 · 6 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Mar 2023 · 24 months · monthly snapshot~Mar 2023 – ~Sep 2023 · 6 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Unknown Status → Completed

  4. Mar 2023 — Sep 2023 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Active Not Recruiting → Unknown Status

  5. Mar 2021 — Mar 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 11 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2019 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  4. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jun 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  6. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

  7. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jun 2018 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  9. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  10. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

  11. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Guangdong Provincial Hospital of Traditional Chinese Medicine
Data source: Guangdong Provincial Hospital of Traditional Chinese Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations